# Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

> **NCT02787447** · PHASE2 · UNKNOWN · sponsor: **First People's Hospital of Hangzhou** · enrollment: 46 (estimated)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

- **DRUG:** TKI
- **RADIATION:** Thoracic Hypofractionated Radiotherapy
- **DRUG:** Thymosin Alpha 1

## Key facts

- **NCT ID:** NCT02787447
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2017-12
- **Final completion:** 2020-05
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2016-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02787447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02787447, "Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02787447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*